A novel antisense medicine, previously dropped by Roche (ROG: SIX), is to be picked up again in the hope of making a breakthrough in Huntington's disease (HD).
Out-licensed to the Swiss firm in 2017 by American biotech Ionis Pharmaceuticals (Nasdaq: IONS), tominersen will be tested in a new Phase II trial.
The surprise decision comes after an exploratory post-hoc analysis suggested the therapy may benefit younger adults with lower disease burden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze